BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance
Molecular Data Will be Analyzed Using Artificial Intelligence Through BERG's Interrogative Biology® Platform to Better Understand Influenza Vaccination Response
BOSTON, Oct. 30, 2017 /PRNewswire/ -- BERG, a biopharmaceutical company that merges biology with technology, today announced a new research effort with Sanofi Pasteur, the influenza vaccine global leader. Under this agreement, BERG will generate and model data using BERG's proprietary Interrogative Biology® platform to assess potential biomarkers of seasonal influenza vaccination outcomes in an unbiased and data-driven manner.
Each year, between 10 and 20 percent of the U.S. population is infected with the influenza virus. When that average is applied nationwide, the flu and its complications lead to more than 200,000 hospital stays per year and tens of thousands of deaths (primarily in the elderly). According to the U.S. Centers for Disease Control and Prevention (CDC), the best method of prevention is to get an annual flu vaccination, which is recommended for everyone six months of age and older, with rare exception.
"We are thrilled to work with Sanofi Pasteur, a world leader in the vaccine industry. The Berg Interrogative Biology® includes multi-omic profiling of samples from individuals participating in a longitudinal study with Sanofi Pasteur licensed vaccines and subsequent use of our bAIcis® artificial intelligence tool with the aim to identify molecular signatures and potential biomarkers indicative of breadth and durability of the Influenza vaccine immunological response," said Niven R. Narain, BERG Co-Founder, President and Chief Executive Officer of BERG.
BERG's Interrogative Biology® platform uses bAIcis® artificial intelligence for data driven analysis of high throughput molecular and clinical information. It is a proven methodology in extracting actionable insights from disparate and unmanageably large (by conventional standards) data sets. As an innovator in precision medicine, BERG has been employing AI in its work towards the discovery of novel predictive and prognostic biomarkers in oncology, neurology and diabetes.
"The Sanofi Pasteur project showcases the versatility and ability of our technology to address important health outcomes questions in the area of infectious diseases both at the individual and population levels," said Slava Akmaev, Senior Vice President and Chief Analytics Officer at BERG. "We are excited to work with Sanofi Pasteur to discover biomarkers of the flu vaccine response, and ultimately on helping to prevent the spread of this debilitating, and sometimes fatal illness."
BERG is a clinical-stage company disrupting and re-defining the approach to drug discovery, research and development through its Interrogative Biology® platform. Its platform identifies therapies and biomarkers by applying algorithm- and probability-based artificial intelligence to analyze large numbers of patients' genotypic, phenotypic and other characteristics. BERG's platform operates at the intersection of biology, technology and artificial intelligence analytics and integrates many data characteristics regarding patients' lifestyles, demographics and biology. BERG believes this allows the company to better understand patients' disease profiles and consequently to identify and reveal molecular signatures to guide and accelerate product candidate selection and development. By identifying biomarkers and patient characteristics that are unique to the disease state, BERG is able to identify novel therapeutic product candidates and develop companion diagnostics to enhance specificity in its drug development process. BERG has leveraged its Interrogative Biology® platform to develop a robust pipeline of therapeutic product candidates and diagnostics in cancer, diabetes and neurology.
For additional information, please visit www.BERGhealth.com